Menu

Impact Events

More
Date Lead
Company
Event Type Approval
Change
Approval
Likelihood
6/21/18 Incyte (INCY) Jakafi for Graft vs. Host Disease (GVHD) Subscribers Only Subscribers Only Subscribers Only
6/21/18 Ferring Nocdurna for Urinary Symptoms (e.g. Nocturia, Polyuria) Subscribers Only Subscribers Only Subscribers Only
6/21/18 Shire (SHPG) Cinryze (IV) for Hereditary Angioedema (HAE) Subscribers Only Subscribers Only Subscribers Only
6/21/18 Voyager (VYGR) VY-AADC01 for Parkinson's Disease (PD) Subscribers Only Subscribers Only Subscribers Only
6/20/18 Novo Nordisk (NVO) Oral Semaglutide for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected
Date Range
Lead
Company
Drug Expected
Catalyst
06/23/18 Subscribers Only Subscribers Only Trial Data - Top-Line Results
06/23/18 Subscribers Only Subscribers Only Trial Data - Other
06/23/18 Subscribers Only Subscribers Only Trial Data - Updated Results
06/23/18 Subscribers Only Subscribers Only Trial Data - Other
06/23/18 Subscribers Only Subscribers Only Trial Data - Updated Results
Back to the top Back to the top